Unmodified natural viruses may not offer the same level of exclusivity as genetically engineered viruses

Since large pharmaceutical companies prioritize treatments using modified viruses, our company is looking for advocacy either from venture capitalists who are interested in a short term exit for a go/ no-go decision requiring modest investment of around €5 M or pharmaceutical companies who are producers of acyclovir and wishing to complement conventional antiviral therapy with the adjuvant immunostimulatory IBDV therapy.

We have solved the problem of reproduceable production

With reverse engineering technology a conventionally produced vaccine virus was recreated as the artificial IBDV R903/78 virus. The two viruses have identical genomes, but the later can be manufactured without any concerns of labor intensive re-plaquing in case of the appearance of contaminant quasispecies or interfering small plaque mutant viruses, which is especially important if the virus is to be used in human therapy. Our orally administered natural virus-based drug candidate does not require specialized delivery methods or monitoring systems (other than observation of crusting of the ulcerated vesicles) to ensure their effectiveness and safety in herpes zoster patients.